Litigation Details for Blue Cross and Blue Shield of Florida, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2021)
✉ Email this page to a colleague
Blue Cross and Blue Shield of Florida, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-12-12 |
| Court | District Court, N.D. California | Date Terminated | |
| Cause | Assigned To | Edward Milton Chen | |
| Jury Demand | Referred To | ||
| Patents | 6,043,230; 6,639,071; 6,642,245; 6,703,396; 6,939,964 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Blue Cross and Blue Shield of Florida, Inc. v. Gilead Sciences, Inc.
Biologic Drugs cited in Blue Cross and Blue Shield of Florida, Inc. v. Gilead Sciences, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Blue Cross and Blue Shield of Florida, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-13 | 1 | Complaint | 18 patent”), and 6,043,230 (“the ’230 patent”) — all derived from the same patent application… 17 Three of the patents — U.S. Patents Nos. 5,922,695 (“the ’695 patent”), 5,977,089 (“the ’089…relevant patent or patents expired, or would have challenged 20 those patents and entered…or, for any later-issued patent, within thirty days of issuance of the patent. 21 U.S.C. …relevance of the manufacturer’s patents. Therefore, in listing patents in the 15 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
